NeurAxis (NASDAQ:NRXS) and MariMed (OTCMKTS:MRMD) Head to Head Contrast

MariMed (OTCMKTS:MRMD) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Institutional & Insider Ownership

0.2% of MariMed shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 17.3% of MariMed shares are owned by company insiders. Comparatively, 21.1% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares MariMed and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MariMed	-9.13%	-10.71%	-2.58%
NeurAxis	-492.76%	N/A	-641.25%

Earnings & Valuation

This table compares MariMed and NeurAxis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MariMed	$159.83 million	0.18	-$14.48 million	($0.04)	-1.82
NeurAxis	$5.32 million	17.72	-$14.63 million	($0.78)	-9.62

MariMed has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than MariMed, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for MariMed and NeurAxis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MariMed	0	2	0	0	2.00
NeurAxis	0	0	1	0	3.00

NeurAxis has a consensus price target of $13.00, indicating a potential upside of 73.33%. Given NeurAxis’ stronger consensus rating and higher possible upside, analysts clearly believe NeurAxis is more favorable than MariMed.

Volatility and Risk

MariMed has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Summary

NeurAxis beats MariMed on 8 of the 14 factors compared between the two stocks.

About MariMed

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.